Having demonstrated that FOXL2 is a shared TAA in GCT and that patients often possess FOXL2-specific T cells, we developed the FoxL2-TT plasmid-DNA vaccine (14) and tested feasibility and efficacy of immunotherapy targeting FOXL2. Here, FOXL2 is linked to granular cell tumor.